ALISO VIEJO, Calif., Dec. 9, 2010 /PRNewswire/ — Clarient, Inc.
(Nasdaq:
CLRT), a premier technology and services resource for
pathologists, oncologists and the pharmaceutical industry, today
announced the commercial launch of Mammostrat, a patented, novel
test designed to help quantify the likelihood of recurrence of
breast cancer following surgery and initial treatment.
The Mammostrat test employs an optimal set of five biomarkers
that are able to be identified visually on a patient’s tumor
specimen by using a well-established technology called
immunohistochemistry. Those biomarkers are then analyzed
using a mathematical algorithm to generate an assessment of risk
for
cancer recurrence.
Mammostrat is well-validated, having been clinically studied on
more than 3,000 women, as reported in multiple peer-reviewed
journals, including Breast Cancer Research (Volume 12,
2010), Clinical Cancer Research (Volume 14, October 2006),
and the Journal of Clinical Oncology (Volume 24, July 2008).
Data from Mammostrat trials have also been presented
at national conferences, including the American Society of Clinical
Oncology (ASCO) and the San Antonio Breast Cancer Symposium.
By using the Mammostrat test pathologists, oncologists and
patients can gain greater understanding of the aggressiveness of a
patient’s disease and guide clinical management. Mammostrat
provides additional clinical information that cannot be obtained
from routinely used prognostic factors. The Mammostrat test can be
performed on small biopsy samples, and results are typically
delivered in as little as 48-72 hours, thereby allowing more rapid
treatment decisions.
“Mammostrat can be an important tool for clinicians assessing
the aggressiveness of their patient’s breast cancer,”
‘/>”/>
